Everolimus and tacrolimus

Hidaka Kono, Ken Nakagawa, Mototsugu Oya

研究成果: Article査読

抄録

The mammalian target of rapamycin (mTOR) protein complex functions as a key protein for proliferation, cell survival, and angiogenesis in intracellular signaling pathways. Everolimus (RAD001), which is one of the mTOR inhibitors, is applied to treat patients with unresectable or metastatic renal cell cancers as second-line treatment for those refractory to sorafenib or sunitinib. Tacrolimus (FK506), which is one of the calcineurin inhibitors, is a strong immunosuppressive agent. Tacrolimus is known as an immunosuppressive agent greatly increasing the risk of malignancy by impairing cancer surveillance, and the drug enhances the production of transforming growth factor β1 (TGF-β1). In cytoplasm, everolimus and tacrolimus bind to the same target, which is called FK506 binding protein 12 (FKBP12), and the complexes play different roles in the cell. We here describe the mechanism of action, the side effects, biomarker, and the role of the two drugs in the future.

本文言語English
ページ(範囲)520-524
ページ数5
ジャーナルBiotherapy
24
6
出版ステータスPublished - 2010 11 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

フィンガープリント 「Everolimus and tacrolimus」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル